UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
SALT LAKE CITY, Aug. 30, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2016 Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016, at the Grand Hyatt New York in New York City.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers (908) 285-0248 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
